Phathom Pharmaceuticals (PHAT) Change in Accured Expenses (2018 - 2026)

Phathom Pharmaceuticals (PHAT) has 9 years of Change in Accured Expenses data on file, last reported at -$3.1 million in Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$3.1 million, up 55.12% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.0 million (down 88.0% YoY), and the FY2025 annual result was $121000.0, down 99.65% from the prior year.
• Change in Accured Expenses grew to -$3.1 million in Q1 2026 per PHAT's latest filing, from -$6.4 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $19.9 million in Q4 2024 and troughed at -$11.3 million in Q1 2023.
• A 5-year average of $2.3 million and a median of $2.9 million in 2023 frame the typical range for Change in Accured Expenses.
• On a YoY basis, Change in Accured Expenses climbed as much as 3654.17% in 2023 and fell as far as 282675.0% in 2023.
• A 5-year view of Change in Accured Expenses shows it stood at $168000.0 in 2022, then surged by 3654.17% to $6.3 million in 2023, then soared by 216.2% to $19.9 million in 2024, then slumped by 132.14% to -$6.4 million in 2025, then soared by 51.26% to -$3.1 million in 2026.
• Business Quant data shows PHAT's Change in Accured Expenses at -$3.1 million in Q1 2026, -$6.4 million in Q4 2025, and $6.5 million in Q3 2025.